Group 1 - The core point of the announcement is that MicroPort Medical (00853) has entered into a merger agreement to acquire CRM Cayman, which will become a wholly-owned subsidiary of MicroPort CardioFlow upon the merger's effectiveness [1][2] - The merger will involve MicroPort CardioFlow issuing new shares at a price of HKD 1.35 per share to the shareholders of CRM Cayman, including its indirect wholly-owned subsidiary, MicroPort International Corp. Limited [1] - Following the merger, CRM Cayman and its subsidiaries will continue to operate as subsidiaries of MicroPort CardioFlow, enhancing the company's overall structure [1] Group 2 - The merger is aligned with MicroPort CardioFlow's strategic development, aiming to establish a globally positioned cardiac product platform that offers a diverse range of products and product pipelines [2] - The anticipated synergies from the merger are expected to expand and diversify MicroPort CardioFlow's existing business, particularly in enhancing its capabilities in structural heart disease and cardiac rhythm disease solutions [2] - The merger will also improve MicroPort CardioFlow's research and development capabilities, manufacturing capacity, distribution channels, and market expansion efforts [2]
微创医疗：微创心通拟合并CRM Cayman 打造心脏病综合解决方案平台